These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31196548)

  • 21. Reactive oxygen species responsive drug releasing nanoparticle based on chondroitin sulfate-anthocyanin nanocomplex for efficient tumor therapy.
    Jeong D; Bae BC; Park SJ; Na K
    J Control Release; 2016 Jan; 222():78-85. PubMed ID: 26686664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-density lipoprotein peptide-combined DNA nanocomplex as an efficient anticancer drug delivery vehicle.
    Zhang N; Tao J; Hua H; Sun P; Zhao Y
    Eur J Pharm Biopharm; 2015 Aug; 94():20-9. PubMed ID: 25960329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low molecular weight heparin-based reduction-sensitive nanoparticles for antitumor and anti-metastasis of orthotopic breast cancer.
    Sun H; Cao D; Liu Y; Wang H; Ke X; Ci T
    Biomater Sci; 2018 Jul; 6(8):2172-2188. PubMed ID: 29942949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics.
    Chun C; Lee SM; Kim CW; Hong KY; Kim SY; Yang HK; Song SC
    Biomaterials; 2009 Sep; 30(27):4752-62. PubMed ID: 19520429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy.
    Li Y; Wu Y; Huang L; Miao L; Zhou J; Satterlee AB; Yao J
    J Control Release; 2016 Apr; 228():107-119. PubMed ID: 26941036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G; Hatakeyama H; Sato Y; Harashima H
    Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
    Sheng Y; You Y; Chen Y
    Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
    Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
    Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.
    Adulnirath A; Chung SW; Park J; Hwang SR; Kim JY; Yang VC; Kim SY; Moon HT; Byun Y
    J Control Release; 2012 Nov; 164(1):8-16. PubMed ID: 23063549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-reduction antiangiogenic curcumin-low molecular weight heparin nanodrugs for enhanced combinational antitumor therapy.
    Xiao Y; Xu C; Xiong H; Du S; Zhou J; Yin L; Yao J
    Eur J Pharm Sci; 2018 Jul; 119():121-134. PubMed ID: 29635010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
    Liu N; Tan Y; Hu Y; Meng T; Wen L; Liu J; Cheng B; Yuan H; Huang X; Hu F
    ACS Appl Mater Interfaces; 2016 Dec; 8(48):33148-33156. PubMed ID: 27934140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties.
    Bae SM; Kim JH; Chung SW; Byun Y; Kim SY; Lee BH; Kim IS; Park RW
    Biomaterials; 2013 Mar; 34(8):2077-86. PubMed ID: 23245333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
    Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
    Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway.
    Choi JU; Chung SW; Al-Hilal TA; Alam F; Park J; Mahmud F; Jeong JH; Kim SY; Byun Y
    Biomaterials; 2017 Sep; 139():56-66. PubMed ID: 28586719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor and Antimetastasis Activities of Heparin-based Micelle Served As Both Carrier and Drug.
    Mei L; Liu Y; Zhang H; Zhang Z; Gao H; He Q
    ACS Appl Mater Interfaces; 2016 Apr; 8(15):9577-89. PubMed ID: 27058058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of primary and metastatic tumors in mice by E-selectin-targeted polymer-drug conjugates.
    Shamay Y; Raviv L; Golan M; Voronov E; Apte RN; David A
    J Control Release; 2015 Nov; 217():102-12. PubMed ID: 26297207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
    Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
    J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Charge Reversible and Mitochondria/Nucleus Dual Target Lipid Hybrid Nanoparticles To Enhance Antitumor Activity of Doxorubicin.
    Song YF; Liu DZ; Cheng Y; Teng ZH; Cui H; Liu M; Zhang BL; Mei QB; Zhou SY
    Mol Pharm; 2018 Mar; 15(3):1296-1308. PubMed ID: 29432025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.